Search Result

Results for "

integrin+αv

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (2) Endogenous Metabolite (2) ERK (1) FAK (1) Fluorescent Dye (1) Integrin (35) MMP (1) PD-1/PD-L1 (2) PI3K (1) Radionuclide-Drug Conjugates (RDCs) (2) Reference Standards (1) TGF-beta/Smad (1) TGF-β Receptor (2)
By Research Areas:	Cancer (28) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-149136

MORF-627	Integrin TGF-beta/Smad	Inflammation/Immunology
MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .

HY-19767

GSK 3008348 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-19767A

GSK 3008348 hydrochloride 2 Publications Verification	Integrin TGF-β Receptor	Infection Inflammation/Immunology Cancer
GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC₅₀ values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .

HY-P1187

HSDVHK-NH2	Integrin	Cancer
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-18668

Integrin antagonist 27	Integrin	Cancer
Integrin antagonist 27 (Compound 27) is a small molecule integrin αvβ3 antagonist with an affinity of 18 nM. Integrin antagonist 27 can be combined with Paclitaxel (HY-B0015) to selectively target αvβ3-positive metastatic cancer cells. Integrin antagonist 27 is used as an anticancer agent .

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-D2062

ATTO 740 NHS ester	Fluorescent Dye Integrin	Cancer
ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P11339A

c-RGD-SH TFA	Integrin	Cancer
c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and ¹¹¹In can be used for SPECT and NIRF imaging of tumor .

HY-W008859R

Tetrac (Standard) Tetraiodothyroacetic acid (Standard); 3,3',5,5'-Tetraiodothyroacetic acid (Standard)	Reference Standards Integrin Endogenous Metabolite	Cancer
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-P11474

FZ1 peptide	Integrin FAK Akt ERK	Metabolic Disease
FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing .

HY-P10704

C16Y	Integrin	Cancer
C16Y is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-176300

RGD-DA6	Integrin	Cancer
RGD-DA6 is an αvβ3-targeted ligand. RGD-DA6 consists of RGDfK (an integrin αvβ3-targeted RGD peptide), DOTADG, d-Glu, Lys, AMBA, and IPBA. RGD-DA6 can be radiolabeled as an αvβ3-targeted radioligand and used for high-contrast tumor imaging and enhanced anticancer efficacy .

HY-P1187A

HSDVHK-NH2 TFA	Integrin	Cancer
HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P10677

HB-3-20	Integrin	Cancer
HB-3-20 leads to degradation of the cell surface integrin α_Vβ₅. Transglutaminase 2 (TG2) has specificity for HB-3-20 (k_cat/K_M=0.16 μM ^-1min ^-1) .

HY-145314

TC113	Integrin	Cancer
TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin α_vβ₃. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells .

HY-126402

Arg-Gly-Asp TFA	Integrin	Cancer
Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.

HY-171331

AB-3PRGD2	PD-1/PD-L1 Integrin	Cancer
AB-3PRGD2 is a radiotherapeutic agent targeting integrin α_vβ₃. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 ⁺ T cells .

HY-P992085

*Anti-Integrin* αvβ8 Antibody**	Integrin	Inflammation/Immunology
Anti-Integrin αvβ8 Antibody is an anti-human monoclonal antibody targeting integrin αvβ8.

HY-185424

Tri-SM6.1	Integrin	Others
Tri-SM6.1 is a tridentate small-molecule ligand targeting integrin αvβ6. Tri-SM6.1 binds to integrin αvβ6 on epithelial cells to deliver conjugated α-ENaC RNAi agents .

HY-P11773

3P-RGD2	Radionuclide-Drug Conjugates (RDCs) Integrin	Others
3P-RGD2 is a dimeric cyclic RGD (Arg-Gly-Asp) peptide. When radiolabeled with ^99mTc, 3P-RGD2 serves as a selective radiotracer for integrin α_vβ₃. When radiolabeled with ^99mTc, 3P-RGD2 enables single-photon emission computed tomography imaging of integrin α_vβ₃ .

HY-P10704A

C16Y acetate	Integrin	Cancer
C16Y acetate is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acetate acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P11780

KAFDITYVRLKF	Integrin MMP	Neurological Disease Cancer
KAFDITYVRLKF is a selective, competitive integrin α_vβ₃ binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease .

HY-P11774

HYNIC-3P-RGD2	Integrin	Cancer
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin α_vβ₃ (IC₅₀ = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P1654A

A20FMDV2-Cys	Integrin	Cancer
A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a *Integrin* α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Cat. No.	Product Name	Type

HY-D2062

ATTO 740 NHS ester	Fluorescent Dyes
ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

ATTO 740 NHS ester

Fluorescent Dyes

ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .

Cat. No.	Product Name	Type

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

Cat. No.	Product Name	Target	Research Area

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(RGDfV) TFA; C(RGDfV) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .

HY-P1187

HSDVHK-NH2	Integrin	Cancer
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE) is a cyclic RGD peptide targeting integrin αvβ3. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is commonly used for modifying drug loaded nanoparticles. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) is often used in cancer research, such as pancreatic cancer .

HY-P0178

LXW7	Integrin	Inflammation/Immunology
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-P11339

c-RGD-SH	Integrin	Cancer
c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .

HY-P0178A

LXW7 TFA	Integrin	Inflammation/Immunology
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC₅₀ of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .

HY-175323

NOTA-IMB-RGD	Integrin PD-1/PD-L1	Cancer
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer) .

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val) Cyclo(RGDfV); C(RGDfV)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .

HY-P11339A

c-RGD-SH TFA	Integrin	Cancer
c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and ¹¹¹In can be used for SPECT and NIRF imaging of tumor .

HY-P11474

FZ1 peptide	Integrin FAK Akt ERK	Metabolic Disease
FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing .

HY-P10704

C16Y	Integrin	Cancer
C16Y is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-P1187A

HSDVHK-NH2 TFA	Integrin	Cancer
HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC₅₀ of 1.74 pg/mL (2.414 pM) .

HY-P10677

HB-3-20	Integrin	Cancer
HB-3-20 leads to degradation of the cell surface integrin α_Vβ₅. Transglutaminase 2 (TG2) has specificity for HB-3-20 (k_cat/K_M=0.16 μM ^-1min ^-1) .

HY-P11773

3P-RGD2	Radionuclide-Drug Conjugates (RDCs) Integrin	Others
3P-RGD2 is a dimeric cyclic RGD (Arg-Gly-Asp) peptide. When radiolabeled with ^99mTc, 3P-RGD2 serves as a selective radiotracer for integrin α_vβ₃. When radiolabeled with ^99mTc, 3P-RGD2 enables single-photon emission computed tomography imaging of integrin α_vβ₃ .

HY-P10704A

C16Y acetate	Integrin	Cancer
C16Y acetate is a short peptide and an inhibitor of integrins αvβ3 and α5β1. C16Y acetate acts on the cell membrane and exerts its anticancer activity by inhibiting angiogenesis .

HY-P11780

KAFDITYVRLKF	Integrin MMP	Neurological Disease Cancer
KAFDITYVRLKF is a selective, competitive integrin α_vβ₃ binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease .

HY-P11774

HYNIC-3P-RGD2	Integrin	Cancer
HYNIC-3P-RGD2 is a dimeric cyclic RGD peptide with high binding affinity for integrin α_vβ₃ (IC₅₀ = 33 nM). HYNIC-3P-RGD2 acts as a precursor molecule for radiotracers and is used to detect tumor angiogenesis .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P1654A

A20FMDV2-Cys	Integrin	Cancer
A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .

HY-P3335

SU015 DOTA-RGDfK dimer	Integrin Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
SU015 (DOTA-RGDfK dimer) is a *Integrin* α_vβ₅ and α_vβ₃ antagonist. SU015 exhibits comparable affinity for α_vβ₅ and α_vβ₃, with relatively higher potency and specificity compared to other integrins. SU015 inhibits α_vβ₃-mediated cell adhesion to fibrinogen, α_vβ₃-mediated adhesion of activated platelets to osteopontin, and α_vβ₅-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with ⁹⁰Y (i.e., RP697) or ¹⁷⁷Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99183

Abituzumab EMD 525797; DI17E6	Integrin	Cancer
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .

HY-P992085

*Anti-Integrin* αvβ8 Antibody**	Integrin	Inflammation/Immunology
Anti-Integrin αvβ8 Antibody is an anti-human monoclonal antibody targeting integrin αvβ8.

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87744

	Integrin αV Antibody (YA7429)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Integrin αV Antibody (YA7429) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Integrin αV.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

integrin+αv

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Natural
Products